The Latest Cardiac and Vascular News
New guidance reframes HFmrEF as a distinct, clinically meaningful condition requiring consistent recognition and management WASHINGTON, April 22, 2026 /PRNewswire/ — A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the…
LAKE FOREST, Calif., April 22, 2026 /PRNewswire/ — Sonorous Neurovascular, a pioneering medical device company focused on innovative solutions for cerebral venous diseases and neurovascular interventions, today announced that it has received 510(k) clearance from the U.S. Food and Drug…
Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation Exposure and Improve Ergonomic Issues Impacting Health Practitioners HINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today highlighted that the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), recently released updated joint guidelines on occupational protection in interventional radiology. The revised guideline provides important safety guidance to physicians, radiographers, nurses, medical physics experts, and all other staff involved in interventional radiology procedures. The guidelines, which were published in CardioVascular and Interventional Radiology (CVIR), cover updated clinical evidence, new exposure sources and address musculoskeletal risks for interventional radiology staff and, for the first time, include a section on radiation protection during pregnancy for female practitioners. “Part of our mission for the LIBERTY System is to enable physicians to continue improving and saving patients’ lives while protecting their own. LIBERTY’s design aims to reduce radiation exposure and physical strain for physicians and related medical staff, positioning the LIBERTY System as a potential solution to address both the health, and the staffing challenges in interventional care,” commented Harel Gadot, Chairman, CEO & President. “It is very encouraging to see increased emphasis on protecting healthcare providers in the interventional space coming from leading medical societies, such as the American Medical Association (AMA), one of the largest medical associations in the U.S., along with SIR and CIRSE.” Prolonged exposure to radiation may have significant long-term health risks, including cancer, cardiovascular disease, reproductive health effects, and cataracts. These risks have also been cited as contributing to the staffing shortage in the endovascular space, especially in interventional radiology, which currently ranks number two among specialties with highest physician shortages. The burden disproportionately affects women, who often cite radiation exposure and the physical demands of wearing lead aprons as barriers to entering or advancing in the field. The LIBERTY System’s remote operation capabilities enable physicians to work away from the radiation source and in a seated position, potentially lowering musculoskeletal strain while improving workflow efficiency. Along with SIR and CIRSE, occupational protection initiatives are being endorsed by the Society of NeuroInterventional Surgery (SNIS), the Society of Vascular and Interventional Neurology (SVIN), the Society for Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC), the Alliance for Cardiovascular Professionals (ACVP), the American Society of Echocardiography (ASE), the Heart Rhythm Society (HRS), and Society for Vascular Surgery (SVS). Additionally, in late 2025, the American Medical Association (AMA) adopted a new policy to strengthen protections for healthcare professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, as well as education and training to minimize occupational risk to physicians and patients. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Learn more at www.microbotmedical.com and connect on LinkedIn and X. Safe Harbor Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Contacts: IR@microbotmedical.comMedia@microbotmedical.com
Kestra Medical Technologies booth at HRS 2026
Kestra Medical Technologies will showcase its Cardiac Recovery System® platform at Heart Rhythm 2026 (HRS). At Booth 2119, attendees can explore the platform through an immersive multimedia experience, experience the ASSURE® system firsthand, and review clinical data from the ACE-PAS study.
KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it will exhibit at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society (HRS) taking place April 23–26 in Chicago. The company will showcase its Cardiac Recovery System® platform—a modern, integrated approach to managing sudden cardiac arrest (SCA) risk that unites proven therapy, actionable clinical insights, and ongoing patient support to enhance protection and optimize care. Kestra, one of the fastest-growing companies in medical technology, continues to build momentum as clinicians increasingly shift toward more connected approaches to SCA risk management. At HRS, attendees will see why more clinicians are turning to Kestra to improve patient protection and better manage risk during the most vulnerable stages of recovery. The ASSURE® WCD is at the center of the Cardiac Recovery System platform. Insights from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS)—the largest prospective study of wearable defibrillators to date—demonstrate robust real-world performance and continue to guide innovation across the platform. At HRS, Kestra is launching a recently FDA-approved ASSURE WCD algorithm update that builds on market-leading clinical performance and applies real-world data to further enhance patient protection and advance care. “At Kestra, innovation is a core principle, so we are excited to further advance the clinical benefits of the ASSURE WCD with this new algorithm. We’re seeing a clear shift in how clinicians approach SCA risk, with a growing emphasis on patient compliance and connected models of care,” said Brian Webster, President and Chief Executive Officer. “HRS is a pivotal moment to engage with prescribers and demonstrate how our clinically informed innovation is driving that momentum—delivering meaningful improvements for clinicians and their patients.” Kestra will be located at Booth 2119, where attendees can experience the ASSURE system firsthand, explore the Cardiac Recovery System platform through an immersive multimedia experience, and review clinical data from ACE-PAS. About Kestra Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of April 22, 2026. Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in Kestra’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on July 17, 2025, and in other periodic reports filed by Kestra with the SEC. These filings are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/93288f45-4a54-4de1-b66e-207047603f80 CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™.
Novel bioresorbable scaffold demonstrates primary patency rate of 97% at 3 years, indicative of long-term efficacy Achieved 1% post-procedural residual stenosis rate — lowest rate ever reported in a clinical trial of femoropopliteal intervention LOS ALTOS, Calif., April 21, 2026 /PRNewswire/ — Efemoral Medical announced today that at the Charing Cross Symposium in London, […]
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access79% secondary patency at 12 months in complex patient populations supported by low reintervention burden (1.3 patency‑related reintervention rate per patient year) and a 3% clinically relevant access related infection rate CE mark approval enables Xeltis to commercialize aXess™ in Europe EINDHOVEN, The Netherlands, April 21, 2026 (GLOBE NEWSWIRE) — Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announced new 12-month clinical data from the aXess multi-center EU pivotal trial, which enrolled 120 patients in 22 clinical trial sites from 9 European countries, demonstrating the transformative potential of aXess™ in hemodialysis treatment. The 12-month pivotal data demonstrate strong and higher secondary patency of aXess™ compared to conventional arteriovenous grafts (AVG), requiring fewer interventions, lower re-intervention rate compared to standard of care and high infection resistance compared to grafts. The aXess pivotal study enrolled a real-world patient population, in which most (69%) of the patients had previously used a central venous catheter (CVC) and had a failed fistula. Findings demonstrated strong durability outcomes, including 79% secondary patency and a very low patency‑related reintervention rate of 1.3 per patient year, alongside a substantial reduction in infection burden. Compared with alternative access options using published benchmark data, patency‑related reinterventions were 60% lower than AVGs and 30% lower than arteriovenous fistulas (AVF), meaning fewer access procedures for patients. At one year, the access‑related infection rate was 3%, versus 22% for CVCs and 9% for AVGs. These findings build on earlier evidence from the six-month EU pivotal trial results which demonstrated significantly improved clinical outcomes compared with ePTFE AVGs, benchmarked against established objective performance criteria, and reconfirm earlier findings observed across previous studies. Importantly, these outcomes are further reinforced by the durability demonstrated across Xeltis’ broader clinical experience including excellent 24-month first-in-human outcomes from a 20-patient European study, as well as long-term clinical cases with follow-up now exceeding four years, providing compelling evidence of longevity and sustained function over time. Taken together with the newly available 12-month pivotal trial data, this comprehensive body of evidence underscores both the clinical benefit and long-term durability of the technology. CE mark approval was obtained in record time, enabling Xeltis to commercialize aXess™ in Europe. Eliane Schutte, Chief Executive Officer, Xeltis, said: “These are tremendous results and represent the first large-scale clinical dataset of its kind generated in Europe. The data demonstrate that aXess™ is safe and easy to implant, and by 12 months transforms into a tissue-like, pulsating conduit. With this level of clinical evidence, we can now move forward with the commercialization of aXess™ and begin delivering it to patients in real-world clinical practice. Patients deserve better options, and this technology has the potential to transform outcomes and save lives.” Dr. Augusto Ministro, Professor of Vascular Surgery at ULS Santa Maria, Portugal, commented: “The combination of a reduced intervention burden, strong infection resistance, early cannulation capability, and a short time to hemostasis represents a significant advance for patients and clinicians alike. These attributes address many of the persistent challenges associated with conventional vascular access, making aXess™ a highly compelling option for improving durability, usability, and overall patient outcomes.” Dr. An De Vriese, Head of the Dept of Internal Medicine and Division of Nephrology and Infectious Disease at AZ Sint-Jan Brugge, Belgium, and co-Principal Investigator of the study, commented: “The 2 pillars of aXess™ are reduced interventions and low intervention rates. The short time to hemostasis is very important for improving the quality of life of the patient.” Dr. Peter Schneider, Professor of Surgery in the Division of Vascular & Endovascular Surgery at University of California, San Francisco, US, added: “Having endothelium along the entire lumen of what started out as a prosthetic graft is a holy grail in our field that many have tried to achieve. It looks like now we finally have it.” Built on Nobel Prize-winning science, aXess™ leverages Restorex™ breakthrough polymer technology, transforming into the patient’s own tissue, forming a living vessel for sustained vascular access and reducing intervention burden and catheter dependency. The Xeltis team presented these data at The 48th Charing Cross Symposium, London, UK, from 21-23 April 2026. Contacts XeltisEliane Schutte, CEOAlexander Goemans, CFOinfo@xeltis.com Optimum Strategic CommunicationsNick Bastin, Eleanor Cooper, Aoife Minihan +44 (0) 208 078 4357xeltis@optimumcomms.com About XeltisXeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary Restorex™ platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living and long-lasting vessels in place. Xeltis’ most advanced product currently under commercial development is aXessTM, an implantable blood vessel for hemodialysis vascular access. Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases. Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the European Innovation Council and Invest-NL, in addition to other public and private investors. Visit the Xeltis website for more details: https://xeltis.com/
Multi-stakeholder evaluation finds domain-specific AI better aligns with clinical workflows, while general-purpose LLMs fall short in usability and clarity SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ — Rad AI, the leader in AI-powered radiology workflow solutions, announced the…
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.
NEW YORK, April 21, 2026 /PRNewswire/ — UltraGreen Cardiac Technologies, a business unit of UltraGreen.ai (“UltraGreen” or the “Company”), a global leader in digital health solutions, today announced a strategic partnership with LifeSignals, a pioneer in wearable biosensor technology, to…
